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college-de-france.fr (A. Prochiantz), ken.moya@collegHomeoproteins transcription factors can transfer between cells and play important roles in devel-
opment. However, some of these homeoproteins are expressed in the adult, but their function is
unknown. The loss of mesencephalic dopaminergic (mDA) neurons is the cause of Parkinson’s dis-
ease. In mice lacking a functional allele for the Engrailed 1 homeoprotein, mDA neurons progres-
sively die starting about 6 weeks after birth. Infusion of recombinant Engrailed stops the death of
these neurons demonstrating that homeoproteins can be neuroprotective. This has been extended
to retinal ganglion cell neurons (RGCs), which die in glaucoma and optic neuropathies. The homeo-
protein Otx2 promotes the survival of injured adult RGCs both in vitro and in vivo. These examples
raise the possibility that homeoproteins may provide neuroprotection to neurons vulnerable in
other neurodegenerative diseases.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction neurons in the cortex opens and closes the critical period for bin-Homeoproteins are homeodomain-containing transcription fac-
tors that play a crucial role in patterning, neurogenesis and neuro-
nal differentiation during brain development [1–5]. Some of these
factors continue to be expressed in the adult brain but their adult
functions are not well documented. A unique property shared by a
number of homeoproteins is that they can be secreted and inter-
nalized by live cells [6,7]. Homeoprotein non-cell-autonomous
activity represents a novel signaling mechanism with several
established functions. In the case of the visual system, for example,
Pax6 intercellular transfer regulates the size of the eye anlagen [8],
Engrailed secretion by the optic tectum participates in retino-tectal
patterning [9,10] and Otx2 internalization by paravalbumin inter-chemical Societies. Published by E
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Another interesting feature of certain homeoproteins is their
ability to regulate protein translation through interaction with
the translation initiation factor eIF4E [12]. The idea that Engrailed
might regulate local translation is also supported by the observa-
tion that Engrailed 1 (En1) is present in the dendrites of midbrain
neurons and that Engrailed growth cone guidance activity requires
local protein translation at the growth cone [9,13]. Beyond their
physiological and developmental interest, the transduction proper-
ties of homeoproteins are particularly attractive in a therapeutic
context. This review addresses the issue of the potential therapeu-
tic use of exogenous Engrailed and Otx2 proteins in animal models
of Parkinson disease and glaucoma. The potential use of cell pene-
trating peptides for the transduction of small peptides or proteins
for neuroprotection or cell replacement therapies is also brieﬂy
discussed.
2. Engrailed and Parkinson’s disease
2.1. Hallmarks and pathogenesis of Parkinson’s disease
Dopamine (DA) plays important functions in several neurologi-
cal and psychiatric disorders [14,15]. Mesencephalic dopaminergic
(mDA) neurons in the ventral midbrain represent the main sourcelsevier B.V. All rights reserved.
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substantia nigra pars compacta (SNpc) innervate the dorsal stria-
tum and form the nigrostriatal pathway that is involved in the con-
trol of voluntary movements. mDA neurons of the ventral
tegmental area (VTA) project to various areas such as nucleus
accumbens, cortex, septum, amygdala and olfactory tubercle to
form the meso-limbic and meso-cortical pathways involved in
emotion-based behaviors such as motivation and reward, as well
in some speciﬁc learning tasks (Fig. 1A).
The main hallmark of PD, the second most common neurode-
generative disorder, is a slow and progressive death of mDA neu-
rons in the SNpc and to a lesser degree in the VTA. mDA cell loss
is associated with the presence of intraneuronal inclusions, called
Lewy bodies, containing mainly a-synuclein, neuroﬁlaments and
ubiquitin [16,17]. This loss ultimately results in severe dopamine
deﬁciency in the striatum responsible for typical PD-associated
motor symptoms such as akinesia, bradykinesia, tremor, rigidity
and loss of postural control [16]. As mentioned above, mDA neu-
rons of the VTA and other non-nigral areas are relatively spared
but their milder loss nonetheless leads to psychiatric disorders
and dementia associated with PD in about 30% of all PD cases
[16,17]. Unfortunately, PD progresses asymptomatically for several
years before the ﬁrst motor symptoms appear when almost 80% of
mDA neurons are lost. Currently available therapies (i.e., L-DOPA
administration, or subthalamic stimulation) are not preventive
and do not slow mDA cell loss.
Apart from familial monogenic forms of PD in which certain
mutated genes have been identiﬁed (i.e., a-synuclein, Pink1, Par-
kin, DJ-1 and Lrrk2), the molecular basis of sporadic idiopathic
PD remains largely unknown. However, it has emerged from
several studies that protein misfolding and dysfunction of the
ubiquitin-proteasome pathway, as well as oxidative stress and
mitochondrial dysfunction play pivotal roles inmDAneurodegener-
ation [18]. Studies following the discovery that 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridium (MPTP) could cause PD in humans
have pointed to mitochondrial complex I impairment as a major
culprit in PD pathogenesis [19]. Most of the mutations found in
human PD genes also affectmitochondrial integrity and/or function,
directly or indirectly. More recently, ﬁndings showing transfer of
a-synuclein between glia and neurons have brought new insights
into the mechanisms of disease progression [20–22].
2.2. Engrailed as a survival factor for mDA neurons in the adult
A detailed knowledge of the genes and mechanisms that govern
mDA neuron development and survival could provide new thera-
peutic strategies to prevent or halt the loss of mDA neurons and/
or restore their function. In this respect, tremendous progress has
been made in the recent years in dissecting the genetic networks
and signaling pathways involved in mDA neuron development.
These studies have established that induction, speciﬁcation, matu-
ration, maintenance and survival of these neurons are regulated by
the concerted action of signaling molecules of the Shh, Fgf8, Tgf-ß
and Wnt pathways and a number of transcription factors including
En-1, Otx2, Pitx3 or Nurr1 [23]. Of particular interest is the fact
that many of these transcription factors remain expressed
throughout adulthood, although their adult functions are not well
characterized. In this context, we were interested in examining the
role of Engrailed in adult mDA neurons.
Loss of function studies have established that Engrailed genes
are required for the survival of embryonic mDA neurons during
development and that pro-survival activity of the genes is dose-
dependent [24–27]. En1 continues to be expressed in adult mDA
neurons of the SNpc and VTA. To examine whether En1 is a survival
factor for adult mDA neurons, En1 heterozygous mice (carrying
only one functional En1 allele; En1+/; En2+/+) were analyzed atvarious ages for mDA survival. We found (Fig. 1B) that the number
of tyrosine hydroxylase (TH)-positive neurons in the SNpc of En1
heterozygous mice started to decline progressively at 6 weeks of
age reaching a 38% reduction (compared to wild-type mice) at
48 weeks [28]. Intriguingly and similarly to PD in humans, progres-
sive mDA cell death was also observed in the VTA but to a lesser
degree (20% at 48 weeks).
The number of mDA neurons in En1 heterozygous mice did not
further decrease in older animals, suggesting that some mDA neu-
ron populations are less dependent upon En1 activity for their sur-
vival. The lower death of VTA mDA cells and the role demonstrated
for Otx2 in the survival of VTA mDA neurons [29,30] suggest that
Otx2 might be contributing to the greater VTA mDA neuronal sur-
vival observed in the En1 heterozygous mice. This latter hypothesis
is also supported by recent data on the pro-survival role of Otx2 in
animal models of glaucoma [31]. This does not eliminate other can-
didates, including other transcription factors. For instance condi-
tional ablation of Nurr1 in the adult using a Cre/loxP strategy
leads to the slow and progressive loss of mDA neurons [32]. Thus,
the study of transcription factors that control various steps of mDA
cell development should be extended to a possible role in mDA
neuron maintenance and thus PD pathogenesis in the adult. It is
noteworthy that En1 has recently been identiﬁed as a possible sus-
ceptibility gene for sporadic PD in humans [33].
2.3. Engrailed heterozygous mice as a valuable animal model for PD
A number of transgenic and knockout mouse lines have been
generated using human PD genes to examine the function of these
genes in mDA cell physiology and to develop animal models for PD.
These mice have been and still are very useful to gain insight into
various aspects of PD pathogenesis. However, most of these animal
models do not exhibit key features of PD such as the slow progres-
sive demise of mDA neurons in the SNpc and a decreased sensitiv-
ity of VTA cells. In this respect En1 heterozygous mice may provide
the most faithful model of PD. In support of this possibility are PD-
like motor symptoms (Fig. 1C) that include decreased spontaneous
locomotor activity (distance travelled, rearing), increased amphet-
amine sensitization or decreased motor coordination and sensori-
motor learning (rotarod test) observed in these mice [28]. In
addition, En1 heterozygous mice present non-motor behavioral
symptoms such as an increased depression-like behavior (forced
swimming test), anhedonic-like behavior (decreased saccharine
preference) and poor social interactions that are similar to symp-
toms in patients. These phenotypes suggest that the mesolimbic
system is also affected, probably a consequence of mDA cell death
in the VTA.
We are currently further characterizing this model to unravel
the mechanisms responsible for mDA neuron degeneration result-
ing from En1 haplo-deﬁciency. We are particularly interested in
determining whether degeneration is anterograde or retrograde.
A retrograde degeneration would further tighten the link with
the human pathology.
2.4. Therapeutic potential of Engrailed or Otx2 to prevent mDA cell loss
Homeoprotein internalization and addressing to the cytoplasm
and the nucleus of live cells in vitro and in vivo makes it tempting
to consider these proteins as putative therapeutic molecules. This
property was exploited in a gain of function approach to demon-
strate that En1/2 proteins can function as survival factors for adult
mDA neurons. Engrailed infused dorsal to the SNpc in 6 week-old
En1 heterozygous mice was able to diffuse into the SNpc and to
completely halt mDA cell loss (Fig. 1B) [28]. We are currently eval-
uating the ability of En1/2 to rescue mDA neurons in other
neurotoxic and genetic PD models. As mentioned above, mDA
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Fig. 1. (A) mDA neurons in the SNpc form the nigrostriatal pathway while those in the VTA contribute to mesolimbic and mesocortical pathways. Loss of mDA neurons in the
SNpc results in motor symptoms of PD while loss of VTA mDA neurons leads to cognitive/psychiatric changes. B, left. En1+/mice show a progressive loss of TH-positive mDA
cells of the SNpc that starts at about 6 weeks after birth. Infusing recombinant Engrailed starting at 6 weeks (red line) arrests the loss of mDA cells measured at 9 weeks (red
circle). (B) Right. The loss of mDA neurons in VTA occurs later and is less pronounced as compared to the SNpc. (C) En1+/mice manifest both motor and non-motor PD-like
symptoms. For details see [28].
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that this is due to a greater dependence on Otx2 than En1/2. Con-
ditional knockout of Otx2 in the En1 expression domain in the mid-
brain results in a dramatic reduction of TH-positive projections in
all target areas of VTA mDA neurons whereas projections to the
dorsolateral striatum, a target of mDA neurons of SNpc, are rela-
tively spared [30,34]. In line with the idea that Otx2 is a survival
factor for these neurons in the adult, is the demonstration that
Otx2 gain of function (using lentiviral vectors) protects mDA neu-
rons against MPTP intoxication in both VTA and SNpc [35]. Like
many homeoproteins, Otx2 is also able to transduce cells and has
been used to protect retinal ganglion cells in an excitotoxic model
of glaucoma as described below or to manipulate the critical period
plasticity in the visual cortex [11]. It would be interesting to exam-
ine to what extent Otx2 transduction can protect mDA neurons in
different PD models.3. Otx2 and glaucoma
3.1. The retina and glaucoma
The eye is a window onto the brain with the retina being a part
of the CNS accessible outside of the brain case and the brain blood
barrier. The retina is a sheet of identiﬁed neuronal cells in stereo-
typic layers and has been used as a model in neuroscience (Fig. 2A).
Light is transduced by cone and rod photoreceptors in the outer
nuclear layer that synapse onto bipolar cells in the inner nuclear
layer. Bipolar cells pass on visual information to retinal ganglion
cells (RGCs) that provide the only output from the retina to the
brain via the optic nerve. In addition to this vertical organization
of information transfer, the organization of the retina also permits
horizontal information processing by the horizontal cells in the in-
ner nuclear layer that modulate the synapses between photorecep-
tors and bipolar cells and by amacrine cells that modulate the
information transfer between bipolar cells and the RGCs. Loss of
RGCs due to glaucoma or optic neuropathies leads to irreversible
and profound blindness.
Glaucoma is the second leading cause of blindness in people
over 50 years of age and there are an estimated 67 million cases
in the world today. Although the speciﬁc cause of glaucoma is gen-
erally unknown important risk factors include age, ethnic group,
ocular trauma, diabetes and hypertension. A number of cases are
associated with elevated intraocular pressure, however, not all pa-
tients with elevated intraocular pressure respond to treatment.
Otx2 is a mammalian ortholog of the orthodenticle homeogene
of drosophila [36]. In situ hybridization studies of retina have
shown Otx2 mRNA to be expressed in photoreceptors and bipolar
cells (Fig. 2A), while immunolocalization studies have reported
Otx2 protein in photoreceptors, bipolar cells and RGCs [37,38].
The presence of Otx2 in RGCs in the absence of detectable mRNA
can be explained by the capture by RGCs of the protein released
by photoreceptors and/or bipolar cells [11,39]. The ability of RGCs
to take up extracellular Otx2 was directly shown in experiments in
which recombinant Otx2 was injected into the eye and the protein
was detected in cells of RGC axon targets, the lateral geniculate nu-
cleus and the superior colliculus [11,40]. Based on the ability of
RGCs to take up Otx2 as shown for Engrailed and mDA cells, and
that Engrailed promotes survival of mDA cells (see above) we
hypothesized that Otx2 would stimulate the survival of injured
adult RGCs.
3.2. Otx2 and RGC survival
A ﬁrst series of experiments was conducted using cells cultured
from adult mouse retina. In these cultures 80–90% of injured RGCsdie within 24–48 h. Otx2 in the nM range increased the number of
RGCs 2- to almost 5-fold at 6 days in vitro (Fig. 2B and [31]). In this
type of mixed culture all retinal cell types are put in culture. There-
fore, it is not clear from these results if Otx2 acts directly on the
RGCs or whether Otx2 stimulates the expression of a survival fac-
tor by other cell types. To answer this, RGCs were puriﬁed from
adult rat retina and cultured with or without Otx2. Again, Otx2
in the nM range stimulated RGC survival in a dose-dependent man-
ner, demonstrating that Otx2 acts directly on injured adult RGCs to
promote their survival.
3.3. Otx2 and sparing of visual function
N-Methyl-D-aspartic acid (NMDA) kills RGCs in vivo and has
been proposed as a rapid model of glaucoma [41,42]. Two millimo-
lar NMDA typically reduced the number of RGCs by 33–60% as as-
sessed by counting cyano ﬂuorescent protein-expressing RGCs or
by qPCR for Brn3A, a surrogate marker for RGCs [31]. 30 ng of
Otx2 injected into the eye offered 100% protection against NMDA-
induced RGC excitotoxicity (Fig 2C). This quantity of Otx2 corre-
sponds to an initial dose of about 100 nM before the protein is de-
graded and/or taken up by the general circulation. To evaluate
whether the surviving RGCs remain functional, visual acuity was
assessed with an optomotor test. Intraocular NMDA signiﬁcantly
reduced the number of head turns in response to rotating pattern
of black and white bars at a spatial frequency of 0.375c/d demon-
strating a loss of visual acuity. The number of head turns in mice in-
jected with NMDA and Otx2 was signiﬁcantly greater than in mice
injected with NMDA alone and was not different from the number
before treatment [31]. Thus, Otx2 not only promotes the survival of
RGCs in vivo, but it also prevents the loss of visual function.
3.4. Mechanism of Otx2 RGC survival activity
Otx2 injected into the eye accumulates in retina [31]. At low
therapeutic doses Otx2 is primarily in the ganglion cell layer, how-
ever at higher doses the protein accumulates in cell bodies in all
retinal layers. In the ganglion cell layer exogenous Otx2 can be ob-
served in nuclei and cytoplasm. Previous work on Engrailed
showed that two amino acids in the third helix of the homeodo-
main are essential for protein internalization by cells [43]. By anal-
ogy we mutated the corresponding amino acids in Otx2 and
predicted that the mutated protein would be internalization deﬁ-
cient. Whereas wild type Otx2 accumulated in cell nuclei and cyto-
plasm of cells in the retina, the mutant protein did not [31].
Interestingly, internalization deﬁcient Otx2 did not have any RGC
survival-promoting activity in vitro or in vivo. Thus Otx2 internal-
ization is necessary for Otx2 survival activity.
Additional experiments showed that dissociated adult RGCs in
culture die by apoptosis and that Otx2 survival-promoting activity
can be at least partially attributed to anti-apoptotic action. In vivo,
NMDA causes RGC death by apoptosis and perhaps by other mech-
anisms. The fact that Otx2 protects 100% in vivo is consistent with
an anti-apoptotic activity of the protein [31]. It is currently un-
known if Otx2 blocks an apoptotic pathway or stimulates a pro-
survival pathway by transcriptional and/or translational control
of proteins such as BAD, Bax or Bcl2. Alternatively, but not mutu-
ally exclusive, Otx2 may stimulate rapid production of small effec-
tor molecules.4. Protein transduction for neurodegeneratives diseases
Protein transduction represents an attractive wider approach
for the delivery of therapeutic proteins or peptides to confer neu-
roprotection in the brain or for generating various neuronal types
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Fig. 2. (A) Schematic of the mammalian retina. GCL: Ganglion cell layer; INL: Inner nuclear layer; ONL: outer nuclear layer. (B) Dissociated adult mouse retinal cells were
cultured in deﬁned conditions. RGCs identiﬁed by neuroﬁlament immunoﬂuorescence and the number surviving at 6 days in culture were signiﬁcantly increased when cells
were treated with Otx2. (C) Otx2 protects against the NMDA-induced loss of RGCs in vivo. Thy1/CFP mice were injected with NMDA or NMDA + Otx2 in the right eye and
4 days later the retinae were ﬂat mounted (upper). NMDA greatly reduces CFP-positive RGCs (middle) compared to the non injected eye (left). Otx2 prevents the NMDA-
induced loss of CFP-positive RGCs (right). For details see [31].
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eases. For instance, cell-permeable tat-HSP70 or tat-Bcl2 proteins
have been used to protect mDA neurons against MPTP in vitro or
in vivo [44,45]. The delivery of small peptides using cell penetrat-
ing peptides (CPPs) can also be an original strategy to disrupt pro-
tein-protein interactions in order to interfere with signaling
pathways that are dysregulated in neurodegenerative conditions.
Interestingly, a CPP designed to inhibit c-Jun N-terminal kinase
in this manner was reported to be highly effective in models of
neuronal degeneration following ischemia or against excitotoxic
retinal ganglion cell death [46,47].
Besides potential applications for neuroprotection, protein
transduction has also been used to generate inducible pluripotent
stem cells (iPSCs) for cell replacement therapies [48]. Transfection
of the transcription factors Oct4, Sox2, Klf4 and c-Myc can induce
pluripotency in mouse ﬁbroblasts. Neurons derived from such
reprogrammed ﬁbroblasts can functionally integrate into fetal
brain and improve symptoms of rats with PD-like symptoms. Inter-
estingly, human iPSCs can also be generated by direct transduction
of ﬁbroblasts with these four transcription factors using CPPs [49].
However, an important drawback in the potential use of cellreplacement strategies might arise from the recent observations
that a-synuclein from affected cells can propagate into grafted
dopaminergic neurons, and perhaps into other grafted cells even-
tually neutralizing their therapeutic activity [50].
Finally, protein transduction was recently used to generate new
animalsmodels of PD. Tat-mediateddelivery ofmutateda-synuclein
(A30P or A53T) or wt nitrated a-synuclein to the SNpc can lead to
rapid death of mDA neurons and degeneration of the nigrostriatal
pathway [51,52]. This approachmight be veryuseful to generate gain
of toxic function models of PD in a relatively short time-scale that
would be useful for testing novel therapeutic approaches.
5. Concluding remarks
Here we presented two examples of homeoprotein neuropro-
tection in the adult brain relevant to human neurodegenerative
diseases. The effectiveness of Engrailed and Otx2 homeoproteins
as potential therapeutic molecules in PD and glaucoma derives lar-
gely from their ability to readily cross cell membranes. While this
ability is due to their homeodomains, it is possible that other
regions of these proteins are important or perhaps even necessary
1578 R.L. Joshi et al. / FEBS Letters 585 (2011) 1573–1578for their neuroprotective effects. Homeoproteins can act on several
levels such as gene transcription, protein translation and possibly
epigenetically, and it will be interesting to identify the targets of
their neuroprotective action. Finally, the expression of other
homeoproteins in other brain regions provides a glimmer of hope
that if neuroprotective activity were present in the other proteins
of the family, homeoproteins might provide interesting reagents
for the treatment of other neurodegenerative diseases such as
Alzheimer’s and Huntington’s.
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